Overview

Topical Psoriasis Study for Patients Receiving Biologic Therapy

Status:
Completed

Trial end date:
2016-10-01

Target enrollment:

Participant gender:

Summary

A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks

Phase:

Phase 4

Details

Lead Sponsor:

Psoriasis Treatment Center of Central New Jersey

Collaborator:

Taro Pharmaceuticals USA

Treatments:

Desoximetasone